Regeneron Pharmaceuticals stock faces pressure from ophthalmology competition

Regeneron Pharmaceuticals (REGN) shares recently faced downward pressure, dropping 4.54% to US$752.25. The decline is attributed to competitive developments in the ophthalmology market, specifically regarding the company’s Eylea franchise.

Kodiak Sciences reported that its experimental drugs, Zenkuda and KSI-501, met primary endpoints in a Phase 3 trial. The results showed vision improvements that were non-inferior to the active ingredient in Eylea. This news has raised investor concerns regarding potential market-share erosion and future pricing pressure in retinal care.

Despite the recent pullback, Regeneron maintains a strong long-term profile, with a 90-day share price return of 20.64% and a one-year total shareholder return of 34.84%. The company is scheduled to release its third-quarter earnings results on October 30. Previous earnings reports showed strong growth, including a 17% year-over-year revenue increase driven by sales of Dupixent, Libtayo, and Eylea HD.